Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sanofi - American Depositary Shares
(NQ:
SNY
)
48.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
July 15, 2025
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi - SNY
July 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony
July 11, 2025
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.
Via
Benzinga
Topics
Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
July 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
July 09, 2025
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.
Via
Stocktwits
Topics
ETFs
Government
Stocks
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
July 08, 2025
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.
Via
Benzinga
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
July 07, 2025
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Via
Investor's Business Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
July 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
July 03, 2025
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 30, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
June 28, 2025
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Via
MarketBeat
Why This Biotech Stock Just Doubled In A Single Day
June 26, 2025
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 26, 2025
Via
ACCESS Newswire
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
June 25, 2025
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 25, 2025
Via
ACCESS Newswire
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
June 25, 2025
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 24, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
June 23, 2025
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.
Via
Benzinga
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
June 20, 2025
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.
Via
Benzinga
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
June 20, 2025
The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation.
Via
Stocktwits
Topics
Supply Chain
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 20, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm
June 16, 2025
From
The Schall Law Firm
Via
Business Wire
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
June 15, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 15, 2025
From
Pomerantz LLP
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
June 13, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
June 12, 2025
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.